Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN007 in advanced solid tumors
NCT03415126Phase 1Completed
- Sponsor
- Asana BioSciences, LLC
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERAS-007 in melanoma, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 2 more (7 arms), sponsored by Asana BioSciences, LLC. Primary endpoints: Maximum Tolerated Dose at 21 days and Overall Response Rate at 6 months. Started Jan 2018; status: completed.
02
Drugs
ERAS-007
03
Conditions
melanomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT03415126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415126.